Gerresheimer's Survival Hinges on June Audit and Asset Fire Sale

German packaging firm Gerresheimer faces a survival fight amid widening probes, a major asset sale, and a critical 2026 deadline after accounting violations and a liquidity crunch.

The financial and legal storm engulfing German packaging specialist Gerresheimer shows no sign of abating. As regulatory probes widen and the company scrambles for cash, a critical deadline in June 2026 now dictates its survival strategy. The firm's shares, which closed at EUR 17.26 recently, have shed nearly 68% over the past year, reflecting a profound crisis of confidence.

Central to the turmoil are accounting irregularities concerning "bill-and-hold" agreements. An independent law firm confirmed systematic IFRS violations where revenue was booked prematurely for goods not yet delivered. These errors impacted EUR 35 million in revenue and EUR 24 million in adjusted EBITDA. The scandal has ensnared auditor KPMG, which gave an unqualified audit opinion on the 2024 accounts despite these flaws. Germany's audit oversight body, APAS, has now initiated professional misconduct proceedings against KPMG.

In response to the deepening crisis, Gerresheimer's management is taking drastic steps to shore up liquidity. The company has tasked Morgan Stanley with selling its US drug packaging subsidiary, Centor, which was last valued at EUR 292 million on the books. Concurrently, a glass plant in Chicago is slated for closure by the end of 2026, with production shifting to facilities in Italy and India.

Regulatory pressure is intensifying on multiple fronts. Financial watchdog BaFin has expanded its investigation beyond leasing liabilities to examine a potential delayed impairment of EUR 196.5 million in the Advanced Technologies segment. A separate BaFin probe is scrutinizing the 2025 half-year report, specifically the risk assessment related to the acquisition of Bormioli Pharma. To untangle the accounts, the company has brought in Grant Thornton as a second audit firm.

The legal fallout is spreading rapidly. Shareholder association DSW is preparing damage claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, as well as the supervisory board. The DSW is also examining valuation issues related to goodwill of around EUR 676 million and is considering engaging a litigation financier.

Gerresheimer's normal financial calendar has ground to a complete halt. The publication of the 2025 annual report is postponed until June 2026, with the Q1 report and annual shareholder meeting indefinitely suspended. This breach of contractual reporting obligations has placed the company in technical default, forcing management into urgent negotiations with lenders to secure waivers and avoid a recall of credit lines.

The company's expulsion from the SDAX index on April 10, 2026, has compounded its troubles, triggering forced selling by index-tracking funds. Since the start of the year, the stock is down approximately 39% and trades nearly 74% below its 52-week high.

Financially, Gerresheimer anticipates non-cash impairment charges of EUR 220 to 240 million for the 2025 fiscal year. These stem largely from technology projects at Swiss subsidiary Sensile Medical and the planned US factory closure. The company's revenue forecast of EUR 2.3 to 2.4 billion for 2026 is explicitly conditional on successful credit negotiations and a positive outcome from the BaFin investigations.

All restructuring efforts are converging on a single, inflexible date. By June 2026, Gerresheimer must present a fully audited annual report. Meeting this deadline with regulatory approval is the only way to validate its financial forecasts and maintain crucial banking relationships. Failure would severely constrict its remaining room for maneuver. The next scheduled financial update is the half-year report due on July 14, 2026, leaving every piece of regulatory news until then as a potential catalyst for the volatile stock.